Ophthalmology APIs
The natural compound prostaglandin F₂α (PGF₂α) activates signaling pathways in the eye that reduce intraocular pressure (IOP). A family of PGF₂α analogs, including bimatoprost, latanoprost, latanoprostene bunod, tafluprost, and travoprost, have been developed, and these compounds are more potent than PGF₂α itself in lowering IOP and have fewer side effects. Moreover, they are known to be safe and effective when used in the treatment of glaucoma.
Ophthalmology
Advanced prostaglandin analogues for ocular therapy.
CGMP Latanoprost
CAS: 130209-82-4GMP material from both Cayman Chemical and Cayman Pharma, which conforms to the USP, EP, and IP Monographs, is available. Each site maintains a unique DMF; they have been filed with the US FDA, Canada, India, Japan, several EU member states, and several other countries. Cayman Pharma GMP material has been granted a Certificate of Suitability (CEP) as of 10 June 2025.
CGMP Latanoprostene Bunod
CAS: 860005-21-6GMP material is available, and the DMF for Latanoprostene Bunod is available for customer review upon request. The DMF has been filed with the US FDA.
Retinal Agent
CGMP Tafluprost
CAS: 209860-87-7GMP material is available, and the DMF for Tafluprost is available for customer review upon request. The DMF has been approved by US FDA and filed in EU countries.
IOP Management
CGMP Bimatoprost
CAS: 155206-00-1GMP material is available, and the DMF for Bimatoprost has been approved in Brazil (CADIFA available), India, and filed in USA and Canada.
Molecular Analog
CGMP Travoprost
CAS: 157283-68-6GMP material, which conforms to the USP Monograph, is available. The DMF has been approved in USA, India, Japan, China, several EU member states, and filed in Canada and several other countries.
Expert Registration Support
Connect with our registration specialists to review detailed DMF filings, stability data, or to arrange technical documentation transfers.
Contact Expert